Total Payments
$74,287
2024 Payments
$22,978
Companies
9
Transactions
30
Medicare Patients
76
Medicare Billing
$9,580
Payment Breakdown by Category
Consulting$51,611 (69.5%)
Other$12,420 (16.7%)
Travel$7,459 (10.0%)
Research$2,152 (2.9%)
Food & Beverage$645.03 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $51,611 | 11 | 69.5% |
| Honoraria | $12,420 | 5 | 16.7% |
| Travel and Lodging | $7,459 | 3 | 10.0% |
| Unspecified | $2,152 | 2 | 2.9% |
| Food and Beverage | $645.03 | 9 | 0.9% |
Payments by Type
General
$72,135
28 transactions
Research
$2,152
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | $25,873 | 3 | $0 (2023) |
| AIMMUNE THERAPEUTICS, INC. | $24,838 | 7 | $0 (2024) |
| NESTLE HEALTHCARE NUTRITION INC. | $9,550 | 3 | $0 (2023) |
| Samsung Bioepis Co., Ltd. | $5,251 | 2 | $0 (2021) |
| Organon LLC | $4,590 | 2 | $0 (2023) |
| ABBVIE INC. | $3,660 | 5 | $0 (2022) |
| Boston Scientific Corporation | $440.01 | 6 | $0 (2023) |
| Valeant Pharmaceuticals North America LLC | $69.79 | 1 | $0 (2017) |
| Allergan Inc. | $15.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $22,978 | 6 | AIMMUNE THERAPEUTICS, INC. ($22,978) |
| 2023 | $10,362 | 5 | Organon LLC ($4,590) |
| 2022 | $5,260 | 3 | Nestle HealthCare Nutrition Inc. ($2,100) |
| 2021 | $5,090 | 2 | Nestle HealthCare Nutrition Inc. ($3,850) |
| 2019 | $6,222 | 3 | Samsung Bioepis Co., Ltd. ($4,011) |
| 2018 | $256.09 | 3 | BOSTON SCIENTIFIC CORPORATION ($256.09) |
| 2017 | $24,118 | 8 | Regeneron Pharmaceuticals, Inc. ($23,750) |
All Payment Transactions
30 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/10/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Honoraria | Cash or cash equivalent | $3,600.00 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 04/02/2024 | Aimmune Therapeutics, Inc. | ZENPEP (Drug) | Consulting Fee | Cash or cash equivalent | $7,700.00 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 04/02/2024 | Aimmune Therapeutics, Inc. | ZENPEP (Drug) | Travel and Lodging | Cash or cash equivalent | $6,791.89 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 04/02/2024 | Aimmune Therapeutics, Inc. | ZENPEP (Drug) | Travel and Lodging | Cash or cash equivalent | $655.96 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 03/27/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Honoraria | Cash or cash equivalent | $1,350.00 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 01/31/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Honoraria | Cash or cash equivalent | $2,880.00 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 10/17/2023 | Boston Scientific Corporation | Axios (Device) | Food and Beverage | In-kind items and services | $48.80 | General |
| Category: Axios_ENDO | ||||||
| 05/17/2023 | Organon LLC | — | Honoraria | Cash or cash equivalent | $2,295.00 | General |
| 05/17/2023 | Organon LLC | — | Honoraria | Cash or cash equivalent | $2,295.00 | General |
| 03/15/2023 | NESTLE HEALTHCARE NUTRITION INC. | — | Consulting Fee | Cash or cash equivalent | $3,600.00 | General |
| 03/06/2023 | Regeneron Pharmaceuticals, Inc. | EVKEEZA (Biological) | — | In-kind items and services | $2,123.45 | Research |
| Study: A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SAFETY AND EFFICACY, FOLLOWING REPEAT-DOSE ADMINISTRATION OF EVINACUMAB (ANTI-ANGPTL3) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG) AT RISK FOR ACUTE PANCREATITIS • Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 11/30/2022 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,300.00 | General |
| 10/26/2022 | Nestle HealthCare Nutrition Inc. | — | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| 04/27/2022 | Aimmune Therapeutics, Inc. | ZENPEP (Drug) | Consulting Fee | Cash or cash equivalent | $1,860.00 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 09/02/2021 | Samsung Bioepis Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $1,240.00 | General |
| 01/21/2021 | Nestle HealthCare Nutrition Inc. | ZENPEP (Drug) | Consulting Fee | Cash or cash equivalent | $3,850.00 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 12/17/2019 | Samsung Bioepis Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $4,010.50 | General |
| 10/30/2019 | AbbVie, Inc. | Creon (Drug) | Consulting Fee | Cash or cash equivalent | $2,200.00 | General |
| Category: Endocrinology | ||||||
| 10/30/2019 | AbbVie, Inc. | Creon (Drug) | Travel and Lodging | In-kind items and services | $11.60 | General |
| Category: Endocrinology | ||||||
| 12/03/2018 | BOSTON SCIENTIFIC CORPORATION | AXIOS (Device) | Food and Beverage | In-kind items and services | $55.75 | General |
| Category: STENTS | ||||||
| 12/02/2018 | BOSTON SCIENTIFIC CORPORATION | AXIOS (Device) | Food and Beverage | In-kind items and services | $85.83 | General |
| Category: STENTS | ||||||
| 03/16/2018 | BOSTON SCIENTIFIC CORPORATION | GENERAL THERAPIES (Device) | Food and Beverage | In-kind items and services | $114.51 | General |
| Category: THERAPIES | ||||||
| 12/28/2017 | BOSTON SCIENTIFIC CORPORATION | SPYGLASS (Device) | Food and Beverage | In-kind items and services | $67.56 | General |
| Category: BILIARY DEVICES | ||||||
| 12/06/2017 | Allergan Inc. | NAMZARIC (Drug) | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/17/2017 | BOSTON SCIENTIFIC CORPORATION | SPYGLASS (Device) | Food and Beverage | In-kind items and services | $67.56 | General |
| Category: BILIARY DEVICES | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SAFETY AND EFFICACY, FOLLOWING REPEAT-DOSE ADMINISTRATION OF EVINACUMAB (ANTI-ANGPTL3) IN PATIENTS WITH SEVERE HYPERTRIGLYCERIDEMIA (SHTG) AT RISK FOR ACUTE PANCREATITIS | Regeneron Pharmaceuticals, Inc. | $2,123 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 1 | 20 | 21 | $7,140 | $2,230 |
| 2021 | 2 | 33 | 34 | $14,440 | $4,453 |
| 2020 | 2 | 23 | 28 | $8,880 | $2,897 |
Total Patients
76
Total Services
83
Medicare Billing
$9,580
Procedure Codes
5
All Medicare Procedures & Services
5 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 20 | 21 | $7,140 | $2,230 | 31.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 18 | 18 | $9,000 | $2,732 | 30.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 15 | 16 | $5,440 | $1,720 | 31.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 12 | $6,000 | $1,961 | 32.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 11 | 16 | $2,880 | $936.54 | 32.5% |
About David Whitcomb
David Whitcomb is a Specialist healthcare provider based in Pittsburgh, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1386610459.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, David Whitcomb has received a total of $74,287 in payments from pharmaceutical and medical device companies, with $22,978 received in 2024. These payments were reported across 30 transactions from 9 companies. The most common payment nature is "Consulting Fee" ($51,611).
As a Medicare-enrolled provider, Whitcomb has provided services to 76 Medicare beneficiaries, totaling 83 services with total Medicare billing of $9,580. Data is available for 3 years (2020–2022), covering 5 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Pittsburgh, PA
- Active Since 02/27/2006
- Last Updated 03/25/2021
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1386610459
Products in Payments
- ZENPEP (Drug) $28,688
- Creon (Drug) $2,360
- EVKEEZA (Biological) $2,123
- AXIOS (Device) $141.58
- SPYGLASS (Device) $135.12
- GENERAL THERAPIES (Device) $114.51
- XIFAXAN (Drug) $69.79
- Axios (Device) $48.80
- NAMZARIC (Drug) $15.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Pittsburgh
Dr. Lawrence Crossett, Md, MD
Specialist — Payments: $5.3M
Specialist $5.3M
Dr. James Bradley, Md, MD
Specialist — Payments: $5.0M
Specialist $5.0M
Darrell Triulzi
Specialist — Payments: $3.3M
Specialist $3.3M
Dr. Mark Yazer, Md, MD
Specialist — Payments: $2.4M
Specialist $2.4M
Lirong Qu
Specialist — Payments: $2.4M
Specialist $2.4M
Dr. Miguel Regueiro, Md, MD
Specialist — Payments: $1.4M
Specialist $1.4M